Evaluation of the Eff ectiveness of the Copper (II) Complex with a New Ligand derived from Benzothiazole and Anthranilic Acid as Anticancer and Antioxidant

Abstract

Four steps were used to convert 2-mercaptobenzothiazole into the new ligand (2-((2-((4-(1-((4’-(benzothiazol-2-ylamino)- [1,1’-biphenyl]-4-yl)imino) ethyl) phenyl)imino)-1,2diphenylethylidene) amino)benzoic acid (LH) type of schiff bases: The fi rst step included preparing compound (A) N-(benzothiazol-2-yl)-[1, 1’-biphenyl]-4, 4’-diamine by the reaction 2-mercaptobenzothiazole with benzidine. The second step was prepared the compound(B) 2 OXO-1, 2-diphenylethylidene) amino) benzoic -(( 2- acid by the reacting anthranilic acid with benzil As for the third step, it included the reaction of the product of the fi rest step with 4-aminoacitophenon and the formation compound (C). The fourth step was the preparation ligand (LH) by reacting compound(B) with compound (C). Fourier-transform infrared spectroscopy (FTIR), proton nuclear magnetic resonance (1H-NMR), UV-vis, melting points, molar conductivity, CHN, atomic absorption, magnetic sensitivity, and other measurements were used to determine the structure of the ligand (LH) and its complex with copper (II). The MTT method was used to evaluate the activity of the ligand (LH) and its complex with copper (II) in-vitro as an anticancer (human breast cancer (MCF7). Nd (MTT) assay was used to evaluate the ligand schiff base in-vitro anticancer activity of a Cu(II) complex against human breast cancer MCF7